Today: 28 January 2026
Subscribe
Browse Category

NASDAQ:W News 2 January 2026 - 4 January 2026

Venezuela, Fed bets and jobs data loom: What to know before U.S. stocks open Monday

Venezuela, Fed bets and jobs data loom: What to know before U.S. stocks open Monday

NEW YORK, Jan 4, 2026, 14:38 ET — Market closed Wall Street heads into Monday’s open after President Donald Trump said the United States had captured Venezuelan President Nicolas Maduro and would put the oil-producing nation under temporary American control. Investors said the intervention could trigger a flight to safer assets when trading resumes.  Reuters The timing matters. The market…
4 January 2026
········
Consumer Cyclical Stocks wobble into Monday as Tesla drags XLY and jobs report looms

Consumer Cyclical Stocks wobble into Monday as Tesla drags XLY and jobs report looms

NEW YORK, January 4, 2026, 13:55 ET — Market closed The Consumer Discretionary Select Sector SPDR ETF, a widely followed proxy for consumer cyclical stocks, ended Friday down 0.9% at $118.35 as Tesla and Amazon fell. Consumer cyclical stocks—companies tied to discretionary spending on items like cars and home furnishings—often swing with shifts in jobs and interest-rate expectations. That sensitivity…
4 January 2026
·······
Dow Jones today: Friday rebound lifts the Dow ahead of ISM and jobs data

Dow Jones today: Friday rebound lifts the Dow ahead of ISM and jobs data

NEW YORK, Jan 4, 2026, 12:16 ET — Market closed The Dow Jones Industrial Average ended Friday’s session higher, giving U.S. blue chips a firmer start to 2026 after late-December selling. With Wall Street shut on Sunday, attention shifts to Monday’s open and a fresh run of economic data. Why it matters now: the first full week of January often…
4 January 2026
·········
U.S. stocks brace for Venezuela shock after Trump strike; key jobs report next

U.S. stocks brace for Venezuela shock after Trump strike; key jobs report next

NEW YORK, Jan 4, 2026, 09:32 ET — Market closed U.S. stocks head into Monday’s session with investors bracing for fallout after the United States struck Venezuela and captured President Nicolas Maduro, a weekend escalation that could rattle oil prices and risk appetite when trading resumes.  Reuters The operation landed as Wall Street was closed, leaving markets to price the…
4 January 2026
·······
Stock market today: S&P 500, Nasdaq start 2026 higher as tech rebounds; Intuit sinks on co-founder sale

Stock market today: S&P 500, Nasdaq start 2026 higher as tech rebounds; Intuit sinks on co-founder sale

NEW YORK, Jan 2, 2026, 11:33 ET U.S. stocks rose on Friday, the first trading day of 2026, as investors returned to heavyweight technology names. Intuit fell after a regulatory filing showed co-founder and director Scott Cook sold shares. The opening moves matter because money managers often reset portfolios at the start of the year, amplifying early swings. Investors are…
2 January 2026
········
Stock market today: Nasdaq, S&P 500 futures climb to start 2026 as Nvidia and Baidu rally

Stock market today: Nasdaq, S&P 500 futures climb to start 2026 as Nvidia and Baidu rally

NEW YORK, January 2, 2026, 07:04 ET — Premarket U.S. stock index futures rose on Friday as Wall Street kicked off 2026 with a tech-led rebound after a late-year slide. At 5:45 a.m. ET, S&P 500 E-minis — futures contracts tied to the index — were up 0.60%, Nasdaq 100 E-minis gained 1.05% and Dow E-minis rose 0.35%. Nvidia and…
2 January 2026
···········

Stock Market Today

  • AstraZeneca Stock Seen 7.6% Undervalued Amid Strong Pipeline and Recent Gains
    January 28, 2026, 5:12 AM EST. AstraZeneca (LSE:AZN) shares have gained 10.51% over three months, with a one-year total shareholder return of 26.95%, highlighting rising investor interest. Trading at £138.80 and estimated 7.6% undervalued against a £150.26 fair value, the company's robust late-stage pipeline - focused on oncology, rare diseases, and cardiovascular therapies - underpins growth forecasts. Analysts expect over $10 billion in peak risk-adjusted revenues from new products, supporting future earnings expansion. However, high valuation with a 31.6x price-to-earnings ratio versus European pharma average of 25.9x raises caution, alongside risks like patent expirations, biosimilar competition, and government price controls. Investors can explore personalized valuation models to assess AstraZeneca's outlook amid evolving market dynamics.
Go toTop